Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1644 1647
This examiner grants 66% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18152056 | METHODS OF DIAGNOSING AND TREATING LUPUS | Non-Final OA | BRISTOL-MYERS SQUIBB COMPANY |
| 18964025 | DIMERIC IMMUNOCONJUGATES FOR USE IN TREATING CANCERS AND METHODS OF USE | Final Rejection | Medicovestor, Inc. |
| 18040888 | METHODS OF TREATING MALIGNANT GLIOBLASTOMA | Final Rejection | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK |
| 17998198 | TREATMENT OF PROSTATE CANCER WITH A COMBINATION OF ABIRATERONE ACETATE AND NIRAPARIB | Final Rejection | Janssen Pharmaceutica NV |
| 17085040 | Pharmaceutical Composition for Cancer Treatment | Non-Final OA | Osaka University |
| 18320653 | Methods for Detecting and Treating Irritable Bowel Syndrome | Non-Final OA | Cedars-Sinai Medical Center |
| 18325860 | METHOD OF TREATMENT OF A TUMOR WITH IL-8 ANTIBODY | Non-Final OA | NantBio, Inc. |
| 18318588 | USES OF MESOTHELIN-TARGETED CHIMERIC ANTIGEN RECEPTORS | Non-Final OA | The U.S.A. as Represented by the Secretary, Department of Health and Human Services |
| 18297064 | PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST OVARIAN CANCER AND OTHER CANCERS | Non-Final OA | Immatics Biotechnologies GmbH |
| 17917923 | METHODS AND USES RELATED TO CELL THERAPY ENGINEERED WITH A CHIMERIC ANTIGEN RECEPTOR TARGETING B-CELL MATURATION ANTIGEN | Non-Final OA | Juno Therapeutics, Inc. |
| 18027993 | DISCOVERY AND USE OF IMMUNOGENIC PEPTIDES FOR THE TREATMENT AND PREVENTION OF CANCERS | Non-Final OA | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM |
| 18354966 | ANTIGENIC PEPTIDES FOR PREVENTION AND TREATMENT OF B-CELL MALIGNANCY | Non-Final OA | ENTEROME S.A. |
| 18323722 | MASKED ACTIVATABLE CYTOKINE CONSTRUCTS AND RELATED COMPOSITIONS AND METHOD | Non-Final OA | CytomX Therapeutics, Inc. |
| 17915990 | METHODS AND COMPOSITIONS FOR MODULATING LIPID STORAGE IN ADIPOSE TISSUE | Non-Final OA | MEMORIAL SLOAN KETTERING CANCER CENTER |
| 18249023 | PAN-RAS mRNA CANCER VACCINES | Non-Final OA | RNAimmune, Inc. |
| 18298021 | METHODS FOR TREATING COLON CANCER WITH COMPOSITIONS COMPRISING AMLEXANOX AND IMMUNE CHECKPOINT INHIBITORS | Non-Final OA | MOONSHOT PHARMA LLC |
| 18296710 | IMMUNO ONCOLOGY COMBINATION THERAPY WITH IL-2 CONJUGATES AND PEMBROLIZUMAB | Non-Final OA | Synthorx, Inc. |
| 18030426 | COMPOSITIONS AND METHODS FOR CANCER DIAGNOSIS | Non-Final OA | AOA Dx |
| 18043923 | MODIFIED MYCOBACTERIUM BOVIS VACCINES | Non-Final OA | Valo Therapeutics Oy |
| 17928806 | INORGANIC NANOPARTICLE-BASED VACCINE COMPOSITIONS FOR CANCER TREATMENT | Non-Final OA | Universidad de la Habana |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy